Market Movers Archives | Page 200 of 869 | Smartkarma

Fiserv, Inc. (FI)

166.66 USD +7.53 (+4.73%) Volume: 11.45M

Discover the latest trends in Fiserv, Inc.’s stock price, currently standing at 166.66 USD, which marked a positive shift of +4.73% this trading session with a trading volume of 11.45M, although experiencing a YTD decrease of -18.87%, highlighting the dynamic nature of FI’s market performance.

Latest developments on Fiserv, Inc.

Despite recent challenges, Fiserv, Inc. (NYSE:FI) remains resilient as it navigates through a 25% share price plunge and stock crash. The company recently held its annual shareholders meeting where key decisions were made, leading to fluctuations in the stock price. The CFO’s warning of slow platform growth resulted in a drop in the stock price, further exacerbated by concerns over Clover payment system growth. However, Wolfe Research maintains an outperform rating on Fiserv, adjusting the price target slightly downwards. Market reactions remain mixed, with Fiserv lagging amidst a backdrop of steady Clover growth, reflecting the dynamic nature of the financial markets.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Humana Inc. (HUM)

237.96 USD +10.49 (+4.61%) Volume: 2.54M

Humana Inc.’s stock price surged to 237.96 USD, marking a positive trading session with a 4.61% rise on a trading volume of 2.54M, despite a year-to-date percentage change of -6.21%, indicating a potential recovery momentum in the healthcare sector.

Latest developments on Humana Inc.

Humana Inc. stock saw a 3.53% increase on May 16, despite facing challenges as the company lowered its full-year earnings guidance. Despite this, various investment firms like Deutsche Bank AG and Meridiem Capital Partners LP made significant purchases of shares in Humana Inc., showing confidence in the company’s future. Analysts have been closely monitoring the stock, with StockNews.com even upgrading their rating to “Buy.” Truist Financial, however, has lowered its price target for Humana stock, leading to a decrease in expectations. Overall, while facing some setbacks, Humana Inc. remains a key player in the healthcare industry, with stock movements closely watched by investors and analysts alike.

Humana Inc. on Smartkarma

Analysts on Smartkarma, such as Value Investors Club, have been covering Humana Inc, a company that provides Medicare Advantage plans to around 6 million members. The research report published on Monday, Oct 28, 2024, highlighted how Humana offers government health insurance for seniors through private insurers. The analysis leans towards a bullish sentiment, emphasizing how Medicare Advantage plans aim to promote value-based care relationships with providers and focus on preventative treatment to provide efficient and high-quality care.

Value Investors Club‘s report on Humana Inc, sourced through publicly available information, emphasizes the company’s approach to limiting provider networks, treatments, and incentivizing cost-saving behavior. The research underscores the importance of paying for outcomes rather than the volume of services provided. This insightful analysis on Humana Inc provides investors with valuable information on the company’s operations and strategies in the healthcare industry.

A look at Humana Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Humana Inc. is positioned favorably for the long-term. With high scores in value, dividend, and momentum, the company is showing strength in these areas. This indicates that Humana Inc. is considered a solid investment with good potential for growth and stability. While the scores for growth and resilience are slightly lower, the overall outlook for the company remains positive.

Humana Inc. is a managed health care company that operates in the United States and Puerto Rico. The company offers a range of health care services through various plans and products to different customer segments. With strong scores in value, dividend, and momentum, Humana Inc. is well-positioned for long-term success in the healthcare industry, catering to employer groups, government-sponsored plans, and individuals.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Molina Healthcare, Inc. (MOH)

325.34 USD +11.37 (+3.62%) Volume: 0.52M

Explore the robust performance of Molina Healthcare, Inc.’s stock price, currently standing at 325.34 USD, demonstrating a promising growth of +3.62% in the latest trading session. With a trading volume of 0.52M and an impressive YTD increase of +11.78%, MOH’s stock is carving a noteworthy trajectory in the healthcare sector.

Latest developments on Molina Healthcare, Inc.

Despite daily gains, Molina Healthcare Inc. stock underperformed on Friday compared to its competitors. Hedge funds are showing interest in small-cap healthcare stocks like Molina Healthcare, Inc. (MOH), while Zacks.com featured highlights on the company along with others. In May, Molina Healthcare of Illinois’ Mobile Help Center will be visiting Springfield and returning to Peoria, showcasing the company’s commitment to community outreach. Investors may want to keep an eye on Molina Healthcare stock movements as it continues to navigate the healthcare market.

Molina Healthcare, Inc. on Smartkarma

Analysts on Smartkarma, like Baptista Research, are closely monitoring Molina Healthcare‘s performance. In a recent report titled “Molina Healthcare’s Medical Cost Crisis – How They’re Fighting Back!”, the analysts highlighted the company’s challenges and prospects for future growth. Despite reporting an 8.5% year-over-year growth in adjusted EPS, Molina Healthcare faced higher-than-anticipated medical cost pressure in the Medicaid and Medicare segments, leading to a consolidated medical care ratio (MCR) of 90.2% for the quarter.

Another report from Value Investors Club emphasized Molina Healthcare‘s successful business model in managing Medicaid programs. The company operates in a competitive landscape with few key players in the Managed Medicaid market, giving them an advantage when states put their programs out to bid. With a fixed fee per member in exchange for assuming medical risk, Molina Healthcare effectively minimizes risk for state administrators while providing Managed Medicaid services to low-income individuals.

A look at Molina Healthcare, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Molina Healthcare shows a promising long-term outlook. With high scores in Growth, Resilience, and Momentum, the company is positioned well for future success. The strong Growth score indicates potential for expansion and increased market share, while the Resilience and Momentum scores suggest stability and positive market trends. However, the lower score in Dividend may be a concern for income-seeking investors.

Molina Healthcare Inc. is a managed care organization that focuses on providing healthcare services to low-income families and individuals. With health plans in multiple states and primary care clinics in California, the company plays a crucial role in ensuring access to healthcare for vulnerable populations. Overall, Molina Healthcare‘s Smartkarma Smart Scores paint a picture of a company with solid growth prospects and a strong foundation for long-term success in the healthcare industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Eli Lilly and Company (LLY)

757.39 USD +25.60 (+3.50%) Volume: 4.63M

Eli Lilly and Company’s stock price soars to 757.39 USD, marking a significant trading session increase of +3.50%. Despite a slight YTD decrease of -1.89%, the pharmaceutical giant’s robust trading volume of 4.63M suggests a resilient market presence.

Latest developments on Eli Lilly and Company

Recently, Eli Lilly & Company has been making waves in the pharmaceutical industry with key events driving stock price movements. The company’s focus on research and development has paid off, with a consultancy ranking them at the top among drug companies. Additionally, a $1.3 billion gene therapy deal with Rznomics and a collaboration on a hearing loss treatment further solidify Eli Lilly’s position in the market. However, rivalry with Novo Nordisk has also impacted stock prices, as reports of the latter developing new obesity treatments led to a fall in Eli Lilly’s stock. Despite this, Eli Lilly remains a trending stock with potential for growth, especially as they consider expanding their manufacturing facilities and continue to develop innovative drugs like Zepbound. Overall, investors are keeping a close eye on Eli Lilly & Company as they navigate the competitive pharmaceutical landscape.

A look at Eli Lilly and Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Eli Lilly & Company seems to have a promising long-term outlook. With a Growth score of 4 and a Momentum score of 4, the company appears to be on a positive trajectory for future expansion and performance in the market. Additionally, the company’s Resilience score of 3 indicates a level of stability and ability to withstand market fluctuations. While the Value score is at 2, suggesting some room for improvement in terms of valuation, the Dividend score of 3 indicates a moderate level of dividend payment to investors.

Eli Lilly & Company is a pharmaceutical company that focuses on discovering, developing, and selling pharmaceutical products for both humans and animals. With a diverse product portfolio that includes neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products, the company has a strong presence in countries worldwide. Overall, the Smartkarma Smart Scores paint a picture of a company with solid growth potential, resilience in the market, and a moderate dividend payout, positioning Eli Lilly & Company as a promising player in the pharmaceutical industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Elevance Health, Inc. (ELV)

403.29 USD +13.29 (+3.41%) Volume: 2.54M

Discover the impressive stock price performance of Elevance Health, Inc. (ELV), currently trading at 403.29 USD, up by 3.41% this session with a robust trading volume of 2.54M. Witnessing a considerable YTD increase of 9.32%, ELV’s stock is making notable strides in the market.

Latest developments on Elevance Health, Inc.

Elevance Health, Inc. (ELV) stock faced underperformance on Friday compared to its competitors, despite experiencing daily gains. Investors who have suffered losses are being urged to contact various law firms before the upcoming July 11 class action deadline. The company is facing a class action lawsuit over alleged Medicaid cost misrepresentation, post-COVID costs claims, and securities fraud. Vanguard Group Inc. recently made a strategic acquisition of Elevance Health Inc shares. Investors who have incurred substantial losses are being given the opportunity to lead the class action lawsuit against the health company. With ongoing investigations and legal actions, the stock price movements of Elevance Health, Inc. have been closely monitored by investors and analysts.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

UnitedHealth Group Incorporated (UNH)

291.91 USD +17.56 (+6.40%) Volume: 70.28M

UnitedHealth Group Incorporated’s stock price soars to a robust 291.91 USD, marking an impressive +6.40% surge this trading session, amid a high trading volume of 70.28M. Despite a year-to-date decline of -42.29%, UNH’s stock performance remains a focal point in the market.

Latest developments on UnitedHealth Group Incorporated

UnitedHealth Group stock price movements today have been influenced by a series of events, including the company being under criminal investigation for possible Medicare fraud. Despite a previous slump, analysts have not abandoned the stock, leading to a rise in UnitedHealth’s stock. The CEO, Andrew Witty, also stepped down for personal reasons, adding to the uncertainty surrounding the company. Additionally, UnitedHealth Group is facing challenges as Medicare Advantage issues mount, with reports of a DOJ probe into potential fraud further impacting the stock price. Insider buying and the CEO’s resignation have also contributed to the stock’s fluctuations. Investors are closely monitoring UnitedHealth’s strategic changes amidst the ongoing investigations and leadership changes.

A look at UnitedHealth Group Incorporated Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

UnitedHealth Group Incorporated, a company that owns and manages organized health systems, has received a mixed outlook based on Smartkarma Smart Scores. While the company scored high in areas such as Dividend and Resilience, with a score of 5 and 3 respectively, it scored lower in Value, Growth, and Momentum, with scores of 3 across the board. This suggests that UnitedHealth Group may be a stable choice for investors looking for steady dividends, but may not offer as much potential for growth or momentum in the future.

Overall, UnitedHealth Group’s long-term outlook seems to be steady, with a strong focus on providing dividends to investors. However, the company may need to focus on improving its value, growth, and momentum scores in order to attract more investors looking for higher returns. With a global presence and a focus on providing employer benefit programs, UnitedHealth Group will need to continue adapting to the ever-changing healthcare landscape to maintain its position in the market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Biggest stock gainers today in S&P 500

Biggest stock losers today in S&P 500

What is Smartkarma SmartScore?

It is a compound score for a Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores (Value, Dividend, Growth, Resilience, Momentum scores) computed by Smartkarma.

The best stock screener – Smartkarma SmartScore Screener

Smartkarma’s stock screener, Smartkarma SmartScore Screener, allows you to easily discover undervalued gems, high dividend stocks, and high growth stocks, across multiple countries and sectors.

Explore the Smartkarma SmartScore Screener now.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Moderna, Inc. (MRNA)

24.86 USD +1.21 (+5.12%) Volume: 14.82M

Moderna, Inc.’s stock price shows a promising surge with a 5.12% increase in the recent trading session, standing at 24.86 USD, backed by a robust trading volume of 14.82M. Despite a year-to-date decline of 40.21%, the recent uptick indicates potential for growth, making MRNA a stock to watch.

Latest developments on Moderna, Inc.

Moderna has been making headlines recently with the opening of a new vaccine manufacturing lab in the UK and the initiation of a Phase 1 clinical trial for a novel cancer therapy candidate. Despite facing revenue challenges from a disappointing RSV vaccine launch, the company continues to innovate with its Pan-Tumor Antigen Therapy Candidate. Investor sentiment has been mixed, with Deutsche Bank AG acquiring a significant number of shares while short interest remains high. The stock price movements today reflect a combination of these factors, as Moderna navigates through both challenges and opportunities in the biotech industry.

Moderna, Inc. on Smartkarma

Analysts at Baptista Research have been closely following Moderna Inc.’s financial performance and strategic direction. In their latest report titled “Moderna Inc.: Is Its mRNA Platform Fueling A Multi-Billion-Dollar Pipeline Beyond COVID?”, they highlighted the opportunities and challenges facing the company. Despite a 53% decrease in total revenue for the year 2024, Moderna recorded $3.2 billion in revenue. The company also reported a net loss of $3.6 billion, showing a slight improvement from the previous year.

Another report by Baptista Research titled “Moderna Inc.: Expanding Global Presence For Unmatched Impact! – Major Drivers” focused on Moderna’s financial results for the third quarter of 2024. The analysts noted that the company generated $1.9 billion in revenue with a net income of $13 million. Ending the quarter with $9.2 billion in cash and investments, Moderna showcased a strong financial position. This liquidity provides the company with a solid foundation to support its ongoing and future initiatives, according to the report.

A look at Moderna, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Modern, Inc. is a biotechnology company that specializes in developing messenger RNA therapeutics and vaccines. According to Smartkarma Smart Scores, Moderna scores high in value, resilience, and momentum, indicating a positive long-term outlook for the company. With a strong focus on developing mRNA medicines for various diseases, including infectious, immuno-oncology, and cardiovascular diseases, Moderna’s innovative approach positions it well for future growth and success in the biotechnology industry.

Although Moderna scores lower in dividend and growth according to Smartkarma Smart Scores, its high scores in other areas suggest that the company is well-positioned for long-term success. With a focus on developing cutting-edge mRNA therapeutics and vaccines, Moderna’s innovative approach to addressing various diseases could lead to significant advancements in the field of biotechnology. Overall, Moderna’s strong performance in value, resilience, and momentum bodes well for its future prospects in the industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

China Construction Bank (939)

6.90 HKD -0.03 (-0.43%) Volume: 305.44M

China Construction Bank’s stock price stands at 6.90 HKD, witnessing a marginal drop of 0.43% this trading session, with a high trading volume of 305.44M. Despite the slight dip, the bank’s stock has shown a positive YTD performance with a rise of 6.17%, indicating a steady growth trajectory.

Latest developments on China Construction Bank

China Construction Bank H stock price saw significant movements today following the release of their quarterly earnings report, which exceeded analysts’ expectations. Investors were pleased with the bank’s strong performance, driven by increased loan growth and improved asset quality. Additionally, news of China Construction Bank H‘s plans to expand its digital banking services and invest in technology further boosted investor confidence. However, concerns over rising inflation and potential regulatory challenges in the banking sector have also impacted the stock price. Overall, market sentiment towards China Construction Bank H remains positive, with many analysts maintaining a buy rating on the stock.

China Construction Bank on Smartkarma

Analysts on Smartkarma, including Gaudenz Schneider, are closely monitoring China Construction Bank H as the company prepares to report its annual 2024 financial results on 28 March 2025. Expectations are for muted price movement post-earnings, with a history of dividend increases adding to investor interest. The bank has switched to semi-annual dividends, offering current yields of 6.4% for H shares and 4.7% for A shares.

In the final week of the Hong Kong earnings season, 17 Hang Seng Index companies, including China Construction Bank H, are set to announce their 2024 results and dividends. Analysts like Gaudenz Schneider see various profit opportunities through trading strategies surrounding these earnings. With significant weightings in key indices, such as HSI and HS TECH, investors have the chance to capitalize on potential price movements, changes in dividends, and implied volatility.

A look at China Construction Bank Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

China Construction Bank H is showing strong performance across the board according to Smartkarma Smart Scores. With high scores in Dividend and Momentum, investors can expect steady returns and positive market momentum. The bank’s Value, Growth, and Resilience scores also indicate a solid long-term outlook, making it a promising investment option in the banking sector.

As a comprehensive commercial bank offering a wide range of products and services to both individuals and corporate clients, China Construction Bank Corporation is well-positioned for continued success. With a focus on corporate banking, personal banking, and treasury operations, the bank also provides services such as infrastructure loans, residential mortgages, and bank cards. Overall, the bank’s strong performance in key areas bodes well for its future prospects and financial stability.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Alibaba Group Holding (9988)

124.10 HKD -4.80 (-3.72%) Volume: 135.71M

Alibaba Group Holding’s stock price currently stands at 124.10 HKD, experiencing a decrease of -3.72% this trading session, with a high trading volume of 135.71M. Despite the recent dip, the stock has shown strong performance with a year-to-date increase of +46.84%, showcasing its potential for robust returns.

Latest developments on Alibaba Group Holding

Alibaba Group Holding has been in the spotlight recently, with mixed results leading to fluctuations in its stock price. Despite announcing robust earnings and declaring significant dividends, the Chinese e-commerce giant fell short of revenue estimates for the fourth quarter of 2025. This disappointment, along with concerns about international e-commerce performance and competition, led to a post-earnings selloff and a 5% slide in stock price. However, analysts remain optimistic about Alibaba’s growth potential, particularly in AI technology. Investors are closely watching key metrics and strategic moves, such as Michael Burry’s exit impacting the portfolio by 16.42%. The company’s focus on AI innovation and cloud intelligence revenue growth of 18% year-on-year in FQ4 shows promise for future margin expansion and recovery from recent setbacks.

Alibaba Group Holding on Smartkarma

Analysts on Smartkarma have been closely monitoring the coverage of Alibaba Group Holding. John Ley, in his report “BABA (9988.HK) Earnings: Volatility Setup, Post-Release Price Behavior and Hedge Recommendation”, leans bearish, suggesting a short-vega hedge for downside protection amidst high implied volatility and jump. On the other hand, Gaudenz Schneider’s insights “Alibaba (9988 HK): Top Trades and Strategic Insights from HKEX Options Trading” and “Alibaba (9988 HK): Volatility Surface Favoring Diagonal and Calendar Spreads” take a bullish stance, highlighting various option strategies like Diagonal Spreads and protection against tail events that traders have been employing, indicating a favorable volatility surface for Calendar and Diagonal Spreads.

Furthermore, Travis Lundy’s analysis on “HK Connect SOUTHBOUND Flows (To 18 Apr 2025); Buying of Internet, SOEs, and ETFs Previously Sold” reveals that SOUTHBOUND investors have been net buyers of Alibaba shares, along with other internet giants like Tencent and Meituan. Despite slower gross flows, the overall sentiment remains positive, with record quarterly inflows in Q1. Gaudenz Schneider’s report “Alibaba (9988 HK): Top Trades – Strategies That Stand Out” also echoes a bullish sentiment, highlighting traders’ calculated bets with long volatility strategies and the prevalence of Calendar and Diagonal Spreads in their options trading activities on the Hong Kong Exchange.

A look at Alibaba Group Holding Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Alibaba Group Holding Limited, a company that provides online sales services, has received positive Smart Scores across the board. With a Growth score of 4 and a Resilience score of 4, the company is positioned well for long-term success. Additionally, Alibaba Group Holding received a Momentum score of 5, indicating strong performance in the market. While the company’s Value and Dividend scores are slightly lower, overall, the outlook for Alibaba Group Holding appears to be favorable.

Alibaba Group Holding Limited, a global provider of internet infrastructure and electronic commerce services, has been rated highly on its long-term outlook according to Smartkarma Smart Scores. With strong scores in Growth, Resilience, and Momentum, the company seems well-equipped to thrive in the online sales industry. While the Value and Dividend scores are not as high, Alibaba Group Holding’s overall performance suggests a promising future ahead for the company.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma